ArticleBlood2014
Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation.
Article in Blood, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 123 citations in OpenAlex.
- Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of PelmegPharmacology research & perspectives · 2019Trial
- Pharmacodynamics, safety, and immunogenicity of PelmegPharmacology research & perspectives · 2019Trial
- The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019Trial
- Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors.Haematologica · 2019Trial
- Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Recovery of Unrelated Donors of Bone Marrow: A Prespecified Analysis from the Phase III Blood and Marrow Transplant Clinical Trials Network Protocol 0201.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2016Trial
- Trial
- Reconsidering the role of bone marrow as a graft source in haploidentical allogeneic hematopoietic cell transplantation.Bone marrow transplantation · 2026Article
- Acute Toxicities of Bone Marrow Donation in Unrelated Donors with Sickle Cell Trait: A Center for International Blood and Marrow Transplantation Research Analysis.Transplantation and cellular therapy · 2026Article
- Safety of hematopoietic stem cell donation from young related donors following the lowering of the age of legal adulthood in Japan.International journal of hematology · 2025Article
- Hematopoietic Stem Cell Donors' Experiences of Information and Side-Effects During the First Year After Donation-A Swedish National Study.Journal of clinical apheresis · 2025Article
- Healthy volunteer stem cell donors followed up 10 years after stimulation with biosimilar filgrastim.Transfusion · 2025Article
- Risk of ankylosing spondylitis in long-term follow-up of hematopoietic stem cell donors: impact of HLA-B27 status and donation type.International journal of hematology · 2025Article
- Use of Granulocyte Transfusions in the Management of Severe Infections Among Children with Neutropenia.Journal of personalized medicine · 2024Article
- Long-term outcomes of peripheral blood stem cell unrelated donors mobilized with filgrastim.Blood advances · 2024Observational
- Long-term follow-up of cancer and catastrophic diseases in hematopoietic stem cell donors: a comprehensive matched cohort study.Bone marrow transplantation · 2024Article
- Incidence of cardiovascular disease in healthy Swedish peripheral blood stem cell donors - a nationwide study.Bone marrow transplantation · 2024Article
- Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias.Blood advances · 2023Article
- Small volume bone marrow aspirates with high progenitor cell concentrations maximize cell therapy dose manufacture and substantially reduce donor hemoglobin loss.BMC medicine · 2023Article
- Adverse events related to central venous catheters (CVC) and the influence of CVC characteristics on peripheral blood hematopoietic progenitor cell collection in children.Frontiers in pediatrics · 2023Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 6 institutions in 2 countries.
Funding
Abstract
We compared serious early and late events experienced by 2726 bone marrow (BM) and 6768 peripheral blood stem cell (PBSC) donors who underwent collection of PBSC or BM between 2004 and 2009 as part of a prospective study through the National Marrow Donor Program. Standardized FDA definitions for serious adverse events (SAEs) were used, and all events were reviewed by an independent physician panel. BM donors had an increased risk for SAEs (2.38% for BM vs 0.56% for PBSC; odds ratio [OR], 4.13; P < .001), and women were twice as likely to experience an SAE (OR for men, 0.50; P = .005). Restricting the analysis to life-threatening, unexpected, or chronic/disabling events, BM donors maintained an increased risk for SAEs (0.99% for BM vs 0.31% for PBSC; OR, 3.20; P < .001). Notably, the incidence of cancer, autoimmune illness, and thrombosis after donation was similar in BM vs PBSC donors. In addition, cancer incidence in PBSC donors was less than that reported in the general population (Surveillance, Epidemiology, and End Results Program database). In conclusion, SAEs after donation are rare but more often occurred in BM donors and women. In addition, there was no evidence of increased risk for cancer, autoimmune illness, and stroke in donors receiving granulocyte colony-stimulating factor during this period of observation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.